QuantHealth Raises $45 Million in Series B Funding
QuantHealth, a Tel Aviv-based AI company focused on accelerating and de-risking drug development through clinical trial simulations, has announced the successful completion of its Series B funding round. The company secured $45 million in this round, which was led by Qumra Capital.
Diverse Investor Participation
In addition to Qumra Capital, a range of investors participated in this funding round. These include Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital Fund L.P., Bertelsmann Healthcare Investments, GC Ventures, NewHealth Ventures, Shoni Top Ventures, and Esplanade Ventures. This diverse group of investors highlights the growing interest in AI-driven solutions within the healthcare sector.
Leadership and Vision
QuantHealth was co-founded by Arnon Horev, who serves as the Chief Strategy & Operations Officer, and Orr Inbar, the company's Chief Executive Officer. The founders have been pivotal in steering the company towards its mission of utilizing AI to make drug development processes more efficient and less risky. "This funding will enable us to further advance our platform and expand our capabilities," said CEO Orr Inbar.
Strategic Use of Funds
The newly acquired funds will be directed towards enhancing QuantHealth's AI platform for simulating clinical trials. This enhancement aims to provide pharmaceutical companies with more accurate predictions, thereby speeding up the drug development pipeline and reducing associated risks.
Conclusion
QuantHealth's latest funding round marks a significant step forward in its journey to revolutionize drug development through AI. With substantial backing from notable investors, the company is well-positioned to continue its growth and innovation in the healthcare technology sector.